# **IT Services | Q1FY24 Result Update**



## Revenue miss; Low visibility leads to weaker outlook

- LTIM reported CC Rev growth of 0.1% QoQ (DE: 2%), impacted due to delay in deal ramp-ups in BFSI & retail. OPM expanded by 30bps QoQ to 16.7% (DE: 16.4%) led by Op. Efficiencies part offset by visa cost.
- Management highlighted that Q1 performance is broadly inline but some
  of the spend freeze actions in BFS client continues to extend into Q2 and
  thus would mean LTIM would miss the double digit growth in FY24.
- Given slip in Q1 growth and lower revenue conversion visibility outlook (DE 8% CC in FY24), we believe the current valuations are bit stretched and thus maintain our Sell rating with TP of Rs,4380 valued at 24x FY25E.

## Order inflow improves; but Ramp-ups remain a challenge

LTIM reported order inflow of \$1.41bn (up 4.4% QoQ and TTM of \$5.1bn). Its book-to-bill stood at 1.2 with healthy deal activity and win-ratio across key verticals. Key verticals continues to face headwinds as clients remain cautious. Vertical wise commentary: 1) **BFSI:** Seeing longer decision cycles and slower ramp ups as some clients continuing with hiring freeze; 2)**Hi-Tech:** Witnessing more efficiency based deals (signed one large 5- yr deal) and increased deal activity but extended decision making cycles, 3) **Retail, CPG & TTH:** Seeing increased commitments from clients focus on Modernizing ERP systems.

## OPM improves sequentially as headcount rationalization continues

OPM stood at 16.7%, up 30bps QoQ led by operational efficiencies (+70bps), which got part negated by seasonal visa costs (-20bps) and increased marketing spend (-20bps). During Q1 reclassification of 1,000 employees from delivery to sales led to 120 bps gains in GM while it got increased to SG&A by 120bps, thus EBIT neutral. Management announced wage hike to happen in July as per industry standard and expect to exit FY24 with OPM of 17-18%.

#### Launched Generative AI platform; confident on relative positioning

LTIM launched Canvas.AI, a generative AI platform designed to accelerate the concept to value journey for businesses. Management is confident on its market positioning and is trying to resolve the challenges through superior Technological solutions.

#### Q1FY24 Result (Rs Mn)

Particulars	Q1FY24	Q1FY23	YoY (%)	Q4FY23	QoQ (%)
Revenue	87,021	76,442	13.8	86,910	0.1
Total Expense	70,666	61,505	14.9	70,873	(0.3)
EBITDA	16,355	14,937	9.5	16,037	2.0
Depreciation	1,847	1,664	11.0	1,823	1.3
EBIT	14,508	13,273	9.3	14,214	2.1
Other Income	1,316	1,776	(25.9)	664	98.2
Interest	460	311	47.9	436	5.5
EBT	15,364	14,738	4.2	14,442	6.4
Tax	3,841	3,672	4.6	3,301	16.4
RPAT	11,515	11,057	4.1	11,137	3.4
APAT	11,515	11,057	4.1	11,137	3.4
			(bps)		(bps)
Gross Margin (%)	31.6	31.1	49	29.9	170
EBITDA Margin (%)	18.8	19.5	(75)	18.5	34
NPM (%)	13.2	14.5	(123)	12.8	42
Tax Rate (%)	25.0	24.9	8	22.9	214
EBIT Margin (%)	16.7	17.4	(69)	16.4	32
	,	,	,	,	,

CMP Rs 5,13								
Target / Downside	rget / Downside Rs 4,380 / 1							
NIFTY		1	.9,712					
Scrip Details								
Equity / FV	Rs 2	96mn	/ Rs 1					
Market Cap		Rs !	903bn					
		USD 1	1.0bn					
52-week High/Low	Rs !	5,430/	4,000					
Avg. Volume (no)		57	7,027					
Bloom Code		Lī	IM IN					
Price Performance	1M	3M	12M					
Absolute (%)	6	19	29					
Rel to NIFTY (%)	0	5	6					

#### **Shareholding Pattern**

_	Dec'22	Mar'23	Jun'23
Promoters	68.7	68.7	68.7
MF/Banks/FIs	10.5	11.7	11.7
FIIs	9.2	8.4	8.4
Public / Others	11.6	11.2	11.2

#### Valuation (x)

	FY23A	FY24E	FY25E
P/E	34.5	31.4	28.2
EV/EBITDA	14.4	12.7	11.1
ROE (%)	28.6	27.0	25.9
RoACE (%)	29.7	28.3	27.0

#### Estimates (Rs bn)

	FY23A	FY24E	FY25E
Revenue	331.8	364.0	410.4
EBITDA	61.1	68.3	76.2
PAT	44.1	48.5	54.0
EPS (Rs.)	148.7	163.7	182.3

VP - Research: Rahul Jain Tel: +9122 40969771 E-mail: rahulj@dolatcapital.com

Associate: Pranav Mashruwala Tel: +9122 40969789

nranavm@dolatoanital.com

E-mail: pranavm@dolatcapital.com

Associate: Ayur Bohra Tel: +9122 40969624 E-mail: ayurb@dolatcapital.com



**Exhibit 1: Quarterly performance versus estimates** 

Particulars (Rs mn)		Estim	ates	% Variation		
Particulars (KS IIIII)	Actual	Dolat	Consensus	Dolat	Consensus	Comment
USD Revenue	1,059	1,080	1,064	(2.0)	(0.5)	Revenue miss due to delayed client
INR Revenue	87,021	88,813	87,710	(2.0)	(0.8)	spending
EBIT	14,508	14,565	14,646	(0.4)	(0.9)	OPM beat due op. efficiencies
EBIT Margin (%)	16.7	16.4	16.7	30 bps	0 bps	or wideat due op. emciencies
PAT	11,515	11,611	11,965	(0.8)	(3.8)	Miss due to higher tax rate.

## **Change in Estimates**

Given the Q1 miss, we expect slow recovery due to integration and macro uncertainties and hence revise down USD growth rate by 2.8%/1.7% for FY24E/FY25E. Margin improvement is expected led by improvement in operating efficiencies and lower attrition rates in FY24 and normal wage hike, and thus inched up our estimates by 58bps/41bps for FY24/FY25E, which in turn has led to 1.1%/0.4% increase in our earnings estimates.

**Exhibit 1: Change in Estimates** 

Doublevilous (Do. 1991)	FY22A	FY23A	FY24E				FY25E	
Particulars (Rs. mn)	Actual	Actual	Old	Old New % Chg.		Old	New	% Chg.
USD Revenue	3,503	4,106	4,541	4,416	(2.8)	5,047	4,962	(1.7)
YoY Growth,	27.5	17.2	10.6	7.6	(304 bps)	11.1	12.4	124 bps
INR Revenue	2,61,167	3,31,830	3,74,659	3,64,027	(2.8)	4,17,365	4,10,391	(1.7)
YoY Growth	28.4	27.1	12.9	9.7	(320 bps)	11.4	12.7	134 bps
EBIT	46,564	53,851	60,182	60,593	0.7	67,248	67,819	0.9
EBIT Margin,	17.8	16.2	16.1	16.6	58 bps	16.1	16.5	41 bps
Net Profit	39,484	44,084	47,981	48,516	1.1	53,829	54,049	0.4
EPS (Rs)	133.5	148.7	161.9	163.7	1.1	181.6	182.4	0.4

Source: DART, Company

## What to expect next Quarter

We expect 2% QoQ growth in Q2FY24 owing to ramp ups in deals of Hi-tech vertical. Expect OPM to expand by 6bps QoQ (wage hikes not baked into estimates for Q2 – may impact OPM by another 150bps in case it is effective entire Q2) offset by operating efficiencies. We believe ramp-up if deal wins to remain muted for another 1-2 quarters thus impacting overall FY24 growth.

**Exhibit 2: What to expect next Quarter** 

(Rs Mn)	Q2FY24E	Q1FY24	Q2FY23	QoQ (%)	YoY (%)
USD Revenue	1,079.9	1,058.7	1,021.9	2.0	5.7
INR Revenue	89,090	87,021	82,278	2.4	8.3
EBIT	14,905	14,508	14,397	2.7	3.5
PAT	12,024	11,515	11,885	4.4	1.2
EPS (Rs)	40.6	38.9	40.2	4.4	1.2
EBIT Margin (%)	16.7	16.7	17.5	6 bps	(77 bps)

Source: Company, DART

## **Valuation**

We believe that LTIM's financial performance got affected due to delays in ramp-ups and hiring freeze of BFSI clients, and expect it to deliver Mid-single digit growth in FY24. However, as growth moderates, valuation may moderate further. We currently value LTIM at 24x on FY25E Earnings of Rs. 163.7with TP of Rs. 4,380 per share (implies PEG of 2x; earlier 22x) and maintain SELL Rating on the stock.



**Exhibit 3: Key Assumptions in our Estimates** 

Particulars (Rs mn)	FY22A	FY23A	FY24E	FY25E
CC revenue growth (%)	28.0	20.6	8.0	12.3
USD revenue growth (%)	27.9	17.2	7.6	12.4
INR revenue growth (%)	28.8	27.1	9.7	12.7
EBIT margin (%)	17.8	16.2	16.6	16.5
EPS growth (%)	29.7	11.4	10.1	11.4
USD/INR	74.6	80.8	82.4	82.7

**Exhibit 4: Quarterly and YTD Trend** 

Particulars (Rs mn)	Q1FY23	Q2FY23	Q3FY23	Q4FY23	Q1FY24	YoY (%)	QoQ (%)	FY22	FY23	YoY (%)
USD Revenue	979.5	1,021.9	1,046.7	1,057.5	1,058.7	8.1	0.1	3,502.9	4,105.6	17.2
INR Revenue	76,442	82,278	86,200	86,910	87,021	13.8	0.1	2,61,167	3,31,830	27.1
Operating Expenses	61,505	65,922	72,452	70,873	70,666	14.9	(0.3)	2,08,632	2,70,752	29.8
Cost of revenues	52,655	56,904	61,555	60,923	59,519	13.0	(2.3)	1,74,736	2,32,037	32.8
as % of sales	68.9	69.2	71.4	70.1	68.4	(49 bps)	(170 bps)	66.9	69.9	302 bps
SG&A expenses	8,850	9,018	10,897	9,950	11,147	26.0	12.0	33,896	38,715	14.2
as % of sales	11.6	11.0	12.6	11.4	12.8	123 bps	136 bps	13.0	11.7	(131 bps)
EBITDA	14,937	16,356	13,748	16,037	16,355	9.5	2.0	52,535	61,078	16.3
Depreciation	1,664	1,959	1,781	1,823	1,847	11.0	1.3	5,971	7,227	21.0
EBIT	13,273	14,397	11,967	14,214	14,508	9.3	2.1	46,564	53,851	15.6
Other Income	1,465	1,233	1,139	228	856	(41.6)	275.4	6,449	4,065	(37.0)
PBT	14,738	15,630	13,106	14,442	15,364	4.2	6.4	53,013	57,916	9.2
Total Tax	3,672	3,740	3,099	3,301	3,841	4.6	16.4	13,512	13,812	2.2
Reported PAT	11,066	11,890	10,007	11,141	11,523	4.1	3.4	39,501	44,104	11.7
MI	9	5	2	4	8	(11.1)	100.0	17	20	17.6
PAT after MI	11,057	11,885	10,005	11,137	11,515	4.1	3.4	39,484	44,084	11.7
Reported EPS	36.1	40.2	33.8	37.7	38.9	7.7	3.4	131.8	147.8	12.1
Margins (%)						(bps)	(bps)			(bps)
EBIDTA	19.5	19.9	15.9	18.5	18.8	(75 bps)	34 bps	20.1	18.4	(171 bps)
EBIT	17.4	17.5	13.9	16.4	16.7	(69 bps)	32 bps	17.8	16.2	(160 bps)
EBT	19.3	19.0	15.2	16.6	17.7	(162 bps)	104 bps	20.3	17.5	(284 bps)
PAT	14.5	14.5	11.6	12.8	13.2	(123 bps)	42 bps	15.1	13.3	(183 bps)
Effective Tax rate	24.9	23.9	23.6	22.9	25.0	8 bps	214 bps	25.5	23.8	(164 bps)



## **Earning call KTAs**

- **Revenue:** Revenue grew by 0.1% QoQ in CC terms and 0.1% QoQ in USD impacted due to slower decision making by clients especially in BFSI and retail vertical and impact due to seasonal pass-through in Q4, otherwise revenue would have been 0.9% QoQ in CC.
- Vertical Commentary: BFSI (38% of Rev) vertical grew by -1.2% QoQ. As BFSI clients are currently focusing on cost-takeout deals. Mgmt. is seeing longer decision cycles and slower ramp ups as some clients continuing with hiring freeze. Hi-Tech, Media & Entertainment Vertical (24% of Rev) grew by 3.2% QoQ. Mgmt is witnessing more efficiency based deals (Won one large strategic 5- yr deal to drive efficiency savings) and increased deal activity but extended decision making cycles. Media & Entertainment is experiencing a positive shift towards Al-based products that cater to consumers' personalized needs. This trend is further fueled by the need for cost reduction and vendor consolidation. Manufacturing & Resources (17% of Rev) saw growth of -1% QoQ. Clients are continuing with their strategic investments in Industry 4.0 initiatives, supply chain modernization, and pricing. Retail, CPG & Pharma (15% of Rev) grew by -1.8% QoQ, seeing increased commitment from clients on strategic ERP modernizing initiatives. Health, Lifesciences & Public services (6% of rev) grew by 5% QoQ as big pharma companies are prioritizing divestment of lower-margin businesses Cost headwinds from regulatory policies mandate a focus on efficiency. The medical devices industry is seeing growing interest in as-a-service models
- **Geography:** In terms of geographies, North America contributed 73% (up 1.8% QoQ). Continental Europe, UK and Ireland contributed 15% (-1.2% QoQ) and RoW contributed 12% of revenue (-7.8% QoQ) during the quarter. There is no concern in RoW and the impact was largely related to project completion while pipeline continues to build.
- Overall Order inflow: TCV for Q1 stood at \$1.41bn (up 4.4% from \$1.35bn in Q4) while TTM TCV stood at \$5.1bn, up 4% QoQ. Deal wins are broad-based across verticals & markets.
- Outlook: Management remains uncertain about double-digit growth as highlighted in the
  previous quarter due to delay in ramp-ups especially in BFSI but aspires to achieve it. It
  highlighted client remained cautious on spending owing to macro uncertainties and are
  delaying/deferring the deal start dates; thus impacting growth of the company.
- Talent & Attrition: Headcount stood at 82.7K, a net reduction of 1.8K employees QoQ. LTM Attrition declined to 17.8% (from 20.2% in Q4FY23). It will continue to hire employees in FY24 as required.
- Margin Walk: EBIT margin stood at 16.7%, expanded by 30bps QoQ led by improvement in Utilization (+70bps) offset by visa costs(-20bps) and higher marketing spend (-20bps). Expects to exit margin of 17-18% in FY24.

**Exhibit 5: Vertical-Wise Trend for Q1FY24** 

Vertical	Amount (\$ mn)	Mix (%)	QoQ (%)	YoY (%)	Incremental Revenue (\$ mn)	% Contribution of Incremental Revenue
BFSI	397	38	(1.2)	12.3	(5)	(403)
Hi-Tech, Media & Entertainment	251	24	3.2	0.9	8	641
Manufacturing & Resources	183	17	(1.0)	14.7	(2)	(159)
Retail, CPG, TTH	160	15	(1.8)	4.0	(3)	(249)
Health, Life Sciences & Public Services	68	6	5.0	6.4	3	271
Total	1,059	100	0.1	8.1	1	100

Source: Company, DART


**Exhibit 6: Geography Trend for Q1FY24** 

Vertical	Amount (\$ mn)	Mix (%)	QoQ (%)	YoY (%)	Incremental Revenue (\$ mn)	% Contribution of Incremental Revenue
North America	774	73	1.8	10.2	14	1131
Europe	161	15	(1.2)	7.4	(2)	(161)
ROW	124	12	(7.8)	(2.7)	(10)	(870)
Total	1,059	100	0.1	8.1	1	100




## **Story in Charts**

Exhibit 7: USD Rev. growth was muted at 0.1% QoQ CC




Source: Company, DART

Exhibit 9: BFS Revenue de-grew 1.2% QoQ




Source: Company, DART

Exhibit 11: Headcount saw reduction of 1.8k employees




Source: Company, DART

Exhibit 8: EBIT margin at 16.7% up 30bps QoQ




Source: Company, DART

Exhibit 10: BFSI, Retail and Manufacturing drag Growth



Source: Company, DART

Exhibit 12: Q1 saw increase in Utilization





**Exhibit 13: Operating Metrics** 

Particulars	Q1FY22	Q2FY22	Q3FY22	Q4FY22	Q1FY23	Q2FY23	Q3FY23	Q4FY23	Q1FY24
CC growth (%) (QoQ)	5.9	10.6	7.5	3.2	5.0	5.0	1.9	0.7	0.1
CC growth (%) (YoY)	N.A	N.A	33.0	33.6	N.A	23.1	16.3	13.5	8.1
OPM (%)	16.9	17.6	18.5	18.0	17.3	17.5	13.9	16.4	16.7
Vertical Amount (\$ mn)									
BFSI	278	301	321	338	354	370	391	402	397
Hi-Tech, Media & Entertainment	195	214	227	239	249	259	247	243	251
Manufacturing & Resources	136	149	168	166	160	166	183	185	183
Retail, CPG, TTH	119	141	143	150	154	157	159	163	160
Health, Life Sciences & Public Services	53	55	60	61	65	69	66	65	68
Vertical Growth (QoQ)									
BFSI	N.A	8.2	6.9	5.1	4.7	4.6	5.8	2.7	-1.2
Hi-Tech, Media & Entertainment	N.A	9.6	6.0	5.2	4.3	3.9	(4.5)	(1.5)	3.2
Manufacturing & Resources	N.A	10.0	12.4	(1.2)	(3.8)	3.7	10.6	1.0	-1.0
Retail, CPG, TTH	N.A	18.7	1.7	4.6	2.7	2.3	1.1	2.4	-1.8
Health, Life Sciences & Public Services	N.A	3.6	8.6	2.3	5.9	7.5	(5.1)	(2.2)	5.0
Geography Amount (\$ mn)								-	
North America	554	599	633	663	702	745	757	760	774
Europe	129	150	155	162	150	149	156	163	161
RoW	99	110	130	129	127	128	134	134	124
Geography Growth (QoQ)									
North America	N.A	8.2	5.7	4.8	5.9	6.1	1.6	0.5	1.8
Europe	N.A	16.7	3.2	4.5	(7.6)	(0.4)	4.5	4.4	-1.2
ROW	N.A	10.9	18.6	(1.2)	(1.2)	0.3	4.9	0.2	-7.8
Effort Mix									
Onsite	17.2	16.1	15.6	15	14.7	14.7	14.9	14.9	14.8
Offshore	82.8	83.9	84.4	85	85.3	85.3	85.1	85.1	85.2



**Exhibit 14: Operating Metrics 2** 

Particulars	Q1FY22	Q2FY22	Q3FY22	Q4FY22	Q1FY23	Q2FY23	Q3FY23	Q4FY23	Q1FY24
Client Data									
Number of Active Clients	608	628	650	673	708	719	723	728	723
New Clients Added	21	35	34	29	43	22	28	31	19
1 Million Dollar +	283	301	316	327	337	361	374	383	388
5 Million Dollar +	109	117	120	125	130	137	144	146	148
10 Million Dollar +	66	74	76	76	79	77	81	81	88
20 Million Dollar +	26	30	31	37	40	38	37	38	40
50 Million Dollar +	8	9	9	10	10	11	11	13	13
100 Million Dollar +	2	2	2	2	2	2	2	2	2
Client Amount (\$ mn)									
Top 5 clients	210	217	234	243	263	273	275	269	283
Top 6-10 clients	69	72	78	76	75	78	79	79	78
Top 11-20 clients	84	97	103	108	108	110	120	117	114
Non-Top 20	418	473	503	527	534	561	573	592	583
Client Growth (QoQ)									
Top 5 clients	N.A	3.5	7.7	3.9	7.9	3.9	0.9	(2.4)	5.2
Top 6-10 clients	N.A	5.0	8.2	(2.2)	(1.2)	3.0	1.1	1.0	-1.2
Top 11-20 clients	N.A	6.5	7.4	3.0	4.3	3.4	2.9	(1.9)	2.2
Non-Top 20	N.A	13.1	6.5	4.7	1.3	5.1	2.1	3.4	-1.5
Utilization									
Excluding Trainees	86.1	85.2	84	83.2	83.5	83.5	82.9	81.7	84.8
Attrition % (LTM)	14.5	18.6	22.1	23.8	24	24.1	22.3	20.2	17.8
Employees									
Development	60,603	66,824	70,710	75,869	79,998	82,681	82,197	80,283	77,555
Sales & Support	3,093	3,309	3,463	3,725	4,032	4,255	4,265	4,263	5,183
Total Headcount	63,696	70,133	74,173	79,594	84,030	86,936	86,462	84,546	82,738
Net Addition	N.A	6,437	4,040	5,421	4,436	2,906	(474)	(1,916)	(1,808)



# **Financial Performance**

Revenue Total Expense COGS Employees Cost Other expenses EBIDTA Depreciation EBIT Interest Other Income Exc. / E.O. items EBT	261,167 208,632 174,736 0 33,896 52,535 5,971 46,564 502 7,331 0 53,393	331,830 270,752 232,037 0 38,715 61,078 7,227 53,851 1,504 5,569 0	364,027 295,771 250,429 0 45,343 68,256 7,663 60,593 1,650 5,665	410,391 334,202 283,492 0 50,711 76,189 8,370 67,819 1,659 5,932
COGS Employees Cost Other expenses EBIDTA Depreciation EBIT Interest Other Income Exc. / E.O. items	174,736 0 33,896 <b>52,535</b> 5,971 <b>46,564</b> 502 7,331 0	232,037 0 38,715 <b>61,078</b> 7,227 <b>53,851</b> 1,504 5,569	250,429 0 45,343 <b>68,256</b> 7,663 <b>60,593</b> 1,650 5,665	283,492 0 50,711 <b>76,189</b> 8,370 <b>67,819</b> 1,659
Employees Cost Other expenses EBIDTA Depreciation EBIT Interest Other Income Exc. / E.O. items	0 33,896 <b>52,535</b> 5,971 <b>46,564</b> 502 7,331	0 38,715 <b>61,078</b> 7,227 <b>53,851</b> 1,504 5,569	0 45,343 <b>68,256</b> 7,663 <b>60,593</b> 1,650 5,665	0 50,711 <b>76,189</b> 8,370 <b>67,819</b> 1,659
Other expenses  EBIDTA  Depreciation  EBIT  Interest Other Income  Exc. / E.O. items	33,896 <b>52,535</b> 5,971 <b>46,564</b> 502 7,331 0	38,715 <b>61,078</b> 7,227 <b>53,851</b> 1,504 5,569	45,343 <b>68,256</b> 7,663 <b>60,593</b> 1,650 5,665	50,711 <b>76,189</b> 8,370 <b>67,819</b> 1,659
EBIDTA  Depreciation  EBIT  Interest Other Income  Exc. / E.O. items	<b>52,535</b> 5,971 <b>46,564</b> 502 7,331 0	61,078 7,227 53,851 1,504 5,569	68,256 7,663 60,593 1,650 5,665	<b>76,189</b> 8,370 <b>67,819</b> 1,659
Depreciation  EBIT Interest Other Income Exc. / E.O. items	5,971 <b>46,564</b> 502 7,331 0	7,227 <b>53,851</b> 1,504 5,569	7,663 <b>60,593</b> 1,650 5,665	8,370 <b>67,819</b> 1,659
EBIT Interest Other Income Exc. / E.O. items	<b>46,564</b> 502 7,331 0	<b>53,851</b> 1,504 5,569	<b>60,593</b> 1,650 5,665	<b>67,819</b> 1,659
Interest Other Income Exc. / E.O. items	502 7,331 0	1,504 5,569	1,650 5,665	1,659
Other Income Exc. / E.O. items	7,331 0	5,569	5,665	
Exc. / E.O. items	0			5,932
		0	0	
EBT	53,393		U	0
		57,916	64,608	72,092
Tax	13,512	13,812	16,072	18,023
RPAT	39,864	44,084	48,516	54,049
Minority Interest	17	20	20	20
Profit/Loss share of associates	0	0	0	0
APAT	39,864	44,084	48,516	54,049
Balance Sheet				
(Rs Mn)	FY22A	FY23A	FY24E	FY25E
Sources of Funds				
Equity Capital	296	296	296	296
Minority Interest	57	71	91	111
Reserves & Surplus	142,576	165,625	193,393	223,730
Net Worth	142,872	165,921	193,689	224,026
Total Debt	519	1,253	1,253	1,253
Net Deferred Tax Liability	(282)	(3,662)	(3,662)	(3,662)
Total Capital Employed	143,166	163,583	191,371	221,728

Net Block	32,378	35,025	35,012	34,917
CWIP	4,589	8,126	7,626	7,126
Investments	64,395	60,553	63,303	66,603
Current Assets, Loans & Advances	104,075	127,448	156,606	187,944
Inventories	41	33	33	33
Receivables	45,574	56,234	64,827	71,959
Cash and Bank Balances	14,462	23,389	40,633	61,631
Loans and Advances	0	0	0	0
Other Current Assets	43,998	47,792	51,114	54,321
Less: Current Liabilities & Provisions	62,271	67,569	71,177	74,862
Payables	13,250	12,938	14,408	16,310
Other Current Liabilities	49,021	54,631	56,768	58,552
sub total				
Net Current Assets	41,804	59,879	85,430	113,082
Total Assets	143,166	163,583	191,371	221,728

E – Estimates



Particulars	FY22A	FY23A	FY24E	FY25E
(A) Margins (%)				
Gross Profit Margin	33.1	30.1	31.2	30.9
EBIDTA Margin	20.1	18.4	18.8	18.6
EBIT Margin	17.8	16.2	16.6	16.5
Tax rate	25.3	23.8	24.9	25.0
Net Profit Margin	15.3	13.3	13.3	13.2
(B) As Percentage of Net Sales (%)				
COGS	66.9	69.9	68.8	69.1
Employee	0.0	0.0	0.0	0.0
Other	13.0	11.7	12.5	12.4
(C) Measure of Financial Status				
Gross Debt / Equity	0.0	0.0	0.0	0.0
Interest Coverage	92.8	35.8	36.7	40.9
Inventory days	0	0	0	0
Debtors days	64	62	65	64
Average Cost of Debt	107.6	169.8	131.7	132.4
Payable days	19	14	14	15
Working Capital days	58	66	86	101
FA T/O	8.1	9.5	10.4	11.8
(D) Measures of Investment				
AEPS (Rs)	134.8	148.7	163.7	182.3
CEPS (Rs)	155.0	173.1	189.5	210.6
DPS (Rs)	55.0	60.0	70.0	80.0
Dividend Payout (%)	40.8	40.3	42.8	43.9
BVPS (Rs)	483.0	559.7	653.4	755.7
RoANW (%)	30.8	28.6	27.0	25.9
RoACE (%)	31.2	29.7	28.3	27.0
RoAIC (%)	40.5	40.1	41.7	43.6
(E) Valuation Ratios				
CMP (Rs)	5135	5135	5135	5135
P/E	38.1	34.5	31.4	28.2
Mcap (Rs Mn)	903,142	903,142	903,142	903,142
MCap/ Sales	3.5	2.7	2.5	2.2
EV	889,199	881,006	863,762	842,764
EV/Sales	3.4	2.7	2.4	2.1
EV/EBITDA	16.9	14.4	12.7	11.1
P/BV	10.6	9.2	7.9	6.8
Dividend Yield (%)	1.1	1.2	1.4	1.6
(F) Growth Rate (%)				
Revenue	28.4	27.1	9.7	12.7
EBITDA	19.9	16.3	11.8	11.6
EBIT	22.9	15.6	12.5	11.9
PBT	30.7	8.5	11.6	11.6
APAT	30.9	10.6	10.1	11.4
EPS	30.9	10.3	10.1	11.4



0

4,015

(20,748)

(16,495)

17,244

23,377

40,621

0

4,273

(23,712)

(19,439)

20,999

40,621

61,619

(1,492)

(15,627)

(2,281)

(19,317)

8,915

14,462

23,377

Particulars	FY22A	FY23A	FY24E	FY25E
Profit before tax	39,500	44,103	64,608	72,092
Depreciation & w.o.	5,971	7,227	7,663	8,370
Net Interest Exp	366	(232)	(4,015)	(4,273)
Direct taxes paid	(39)	(1,405)	(16,072)	(18,023)
Change in Working Capital	(12,188)	(17,645)	(8,344)	(6,504)
Non Cash	(1,103)	(1,102)	0	0
(A) CF from Operating Activities	32,507	30,946	43,839	51,663
Capex {(Inc.)/ Dec. in Fixed Assets n WIP}	(12,384)	(10,832)	(7,350)	(7,925)
Free Cash Flow	21,978	21,600	36,489	43,738
(Inc)./ Dec. in Investments	(4,643)	6,257	(2,750)	(3,300)
Other	574	1,266	0	0
(B) CF from Investing Activities	(16,453)	(3,309)	(10,100)	(11,225)
Issue of Equity/ Preference	2	12	0	0
Inc./(Dec.) in Debt	(370)	71	237	0

(1,155)

(13,277)

(2,004)

(16,804)

(729)

15,191

14,462

**Closing Cash balances** E – Estimates

Other

Interest exp net

Dividend Paid (Incl. Tax)

(C) CF from Financing

**Opening Cash balances** 

Net Change in Cash

**Cash Flow** 

Notes



## **DART RATING MATRIX**

**Total Return Expectation (12 Months)** 

Buy	> 20%
Accumulate	10 to 20%
Reduce	0 to 10%
Sell	< 0%

# **Rating and Target Price History**



Month	Rating	TP (Rs.)	Price (Rs.)
Oct-22	Reduce	4,520	4,669
Jan-23	Reduce	4,350	4,268
Mar-23	SELL	3,990	4,567

<sup>\*</sup>Price as on recommendation date

# **DART** Team

Purvag Shah	Managing Director	purvag@dolatcapital.com	+9122 4096 9747
Amit Khurana, CFA	Head of Equities	amit@dolatcapital.com	+9122 4096 9745
	CONTACT DETA	AILS	
Equity Sales	Designation	E-mail	Direct Lines
Dinesh Bajaj	VP - Equity Sales	dineshb@dolatcapital.com	+9122 4096 9709
Kapil Yadav	VP - Equity Sales	kapil@dolatcapital.com	+9122 4096 9735
Jubbin Shah	VP - Equity Sales	jubbins@dolatcapital.com	+9122 4096 9779
Girish Raj Sankunny	VP - Equity Sales	girishr@dolatcapital.com	+9122 4096 9625
Pratik Shroff	AVP - Equity Sales	pratiks@dolatcapital.com	+9122 4096 9621
Equity Trading	Designation	E-mail	
P. Sridhar	SVP and Head of Sales Trading	sridhar@dolatcapital.com	+9122 4096 9728
Chandrakant Ware	VP - Sales Trading	chandrakant@dolatcapital.com	+9122 4096 9707
Shirish Thakkar	VP - Head Domestic Derivatives Sales Trading	shirisht@dolatcapital.com	+9122 4096 9702
Kartik Mehta	Asia Head Derivatives	kartikm@dolatcapital.com	+9122 4096 9715
Bhavin Mehta	VP - Derivatives Strategist	bhavinm@dolatcapital.com	+9122 4096 9705



#### Analyst(s) Certification

The research analyst(s), with respect to each issuer and its securities covered by them in this research report, certify that: All of the views expressed in this research report accurately reflect his or her or their personal views about all of the issuers and their securities; and No part of his or her or their compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed in this research report.

#### I. Analyst(s) and Associate (S) holding in the Stock(s): (Nil)

#### II. Disclaimer:

This research report has been prepared by Dolat Capital Market Private Limited. to provide information about the company(ies) and sector(s), if any, covered in the report and may be distributed by it and/or its affiliated company(ies) solely for the purpose of information of the select recipient of this report. This report and/or any part thereof, may not be duplicated in any form and/or reproduced or redistributed without the prior written consent of Dolat Capital Market Private Limited. This report has been prepared independent of the companies covered herein. Dolat Capital Market Private Limited. and its affiliated companies are part of a multi-service, integrated investment banking, brokerage and financing group. Dolat Capital Market Private Limited. and/or its affiliated company(ies) might have provided or may provide services in respect of managing offerings of securities, corporate finance, investment banking, mergers & acquisitions, financing or any other advisory services to the company(ies) covered herein. Dolat Capital Market Private Limited. and/or its affiliated company(ies) might have received or may receive compensation from the company(ies) mentioned in this report for rendering any of the above services. Research analysts and sales persons of Dolat Capital Market Private Limited. may provide important inputs to its affiliated company(ies) associated with it. While reasonable care has been taken in the preparation of this report, it does not purport to be a complete description of the securities, markets or developments referred to herein, and Dolat Capital Market Private Limited. does not warrant its accuracy or completeness. Dolat Capital Market Private Limited. may not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. This report is provided for information only and is not an investment advice and must not alone be taken as the basis for an investment decision. The investment discussed or views expressed herein may not be suitable for all investors. The user assumes the entire risk of any use made of this information. The information contained herein may be changed without notice and Dolat Capital Market Private Limited. reserves the right to make modifications and alterations to this statement as they may deem fit from time to time. Dolat Capital Market Private Limited. and its affiliated company(ies), their directors and employees may; (a) from time to time, have a long or short position in, and buy or sell the securities of the company(ies) mentioned herein or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions. This report is neither an offer nor solicitation of an offer to buy and/or sell any securities mentioned herein and/or not an official confirmation of any transaction. This report is not directed or intended for distribution to, or use by any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject Dolat Capital Market Private Limited. and/or its affiliated company(ies) to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to a certain category of investors. Persons in whose possession this report may come, are required to inform themselves of and to observe such restrictions.



#### **Dolat** Capital Market Private Limited.

Corporate Identity Number: U65990GJ993PTC116741

Member: BSE Limited and National Stock Exchange of India Limited.

SEBI Registration No: BSE - INZ000274132, NSE - INZ000274132, Research: INH000000685

Regd. office: 1401-1409, Dalal Street Commercial, Block 53 (Bldg. No.53E) Zone-5, Road-5E, Gift City, Sector 9, Gandhinagar-382355 Gujarat, India.

Board: +9122 40969700 | Fax: +9122 22651278 | Email: research@dolatcapital.com | www.dolatresearch.com